Geddes, J, Freemantle, N, Harrison, P, Bebbington, P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ
2000; 321: 1371–6.
Leucht, S, Wahlbeck, K, Hamann, J, Kissling, W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet
2003; 361: 1581–9.
Davis, JM, Chen, N, Glick, ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry
2003; 60: 553–64.
Leucht, S, Corves, C, Arbter, D, Engel, RR, Li, C, Davis, JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet
2009; 373: 31–41.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Jones, PB, Barnes, TR, Davies, L, Dunn, G, Lloyd, H, Hayhurst, KP, et al. Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry
2006; 63: 1079–87.
Rosenheck, RA, Leslie, DL, Sindelar, J, Miller, EA, Lin, H, Stroup, TS, et al; CATIE Study Investigators. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry
2006; 163: 2080–9.
Davies, LM, Lewis, S, Jones, PB, Barnes, TRE, Gaughran, F, Hayhurst, K, et al; CUtLASS team. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry
2007; 191: 14–22.
Large, M, Farooq, S, Nielssen, O, Slade, T. Relationship between gross domestic product and duration of untreated psychosis in low- and middle-income countries. Br J Psychiatry
2008; 193: 272–8.
Lewis, S, Lieberman, J. CATIE and CUtLASS: can we handle the truth?
Br J Psychiatry
2008; 192: 161–3.
Robinson, DG, Woerner, MG, Alvir, JM, Geisler, S, Koreen, A, Sheitman, B, et al. Predictors of treatment response from a first episode of schizophrenia or schizoaffective disorder. Am J Psychiatry
1999; 156: 544–9.
Oosthuizen, P, Emsley, R, Jadri Turner, H, Keyter, N. A randomized, controlled comparison of the efficacy and tolerability of low and high doses of haloperidol in the treatment of first-episode psychosis. Int J Neuropsychopharmacol
2004; 7: 125–31.
Sanger, TM, Lieberman, JA, Tohen, M, Grundy, S, Beasley, C Jr, Tollefson, GD. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry
1999; 156: 79–87.
Smith, M, Hopkins, D, Peveler, RC, Holt, RIG, Woodward, M, Ismail, K. First- v. second-generation antipsychotics and risk for diabetes in schizophrenia: systematic review and meta-analysis. Br J Psychiatry
2008; 192: 406–11.
Cotton, SM, Lambert, M, Schimmelmann, BG, Foley, DL, Morley, KI, McGorry, PD, Conus, P. Gender differences in premorbid, entry, treatment, and outcome characteristics in a treated epidemiological sample of 661 patients with first episode psychosis. Schizophr Res
2009; 114: 17–24.
Rummel, C, Hamann, J, Kissling, W, Leucht, S. New generation antipsychotics for first episode schizophrenia. Cochrane Database Syst Rev
2003; 4: CD004410.
Emsley, R, Rabinowitz, J, Medori, R. Time course for antipsychotic treatment response in first-episode schizophrenia. Am J Psychiatry
2006; 163: 743–5.
Robinson, DG, Woerner, MG, Delman, HM, Kane, JM. Pharmacological treatments for first-episode schizophrenia. Schizophr Bull
2005; 31: 705–22.
DerSimonian, R, Laird, N. Meta-analysis in clinical trials. Control Clin Trials
1986; 7: 177–88.
Egger, M, Davey Smith, G. Systematic Reviews in Health Care: Meta-analysis in Context (2nd edn). BMJ Publishing Group, 2001.
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, et al; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet
2008; 371: 1085–97.
Egger, M, Davey Smith, G, Schneider, M, Minder, C. Bias in meta-analysis detected by a simple, graphical test. BMJ
1997; 315: 629–34.
Emsley, RA. Risperidone in the treatment of first-episode psychotic patients: a double-blind multicenter study. Risperidone Working Group. Schizophr Bull
1999; 25: 721–9.
Mackeprang, T, Kristiansen, KT, Glenthøj, BY. Effects of antipsychotics on prepulse inhibition of the startle response in drug-naïve schizophrenic patients. Biol Psychiatry
2002; 52: 863–73.
Schooler, N, Rabinowitz, J, Davidson, M, Emsley, R, Harvey, PD, Kopala, L, et al; Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry
2005; 162: 947–53.
Wu, RR, Zhao, JP, Liu, ZN, Zhai, JG, Guo, XF, Guo, WB, et al. Effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. Psychopharmacology (Berl)
2006; 186: 572–8.
Crespo-Facorro, B, Pérez-Iglesias, R, Ramirez-Bonilla, M, Martínez-García, O, Llorca, J, Luis Vázquez-Barquero, J. A practical clinical trial comparing haloperidol, risperidone, and olanzapine for the acute treatment of first-episode nonaffective psychosis. J Clin Psychiatry
2006; 67: 1511–21.
Brewer, WJ, Yücel, M, Harrison, BJ, McGorry, PD, Olver, J, Egan, GF, et al. Increased prefrontal cerebral blood flow in first-episode schizophrenia following treatment: longitudinal positron emission tomography study. Aust N Z J Psychiatry
2007; 41: 129–35.
Gaebel, W, Riesbeck, M, Wölwer, W, Klimke, A, Eickhoff, M, von Wilmsdorff, M, et al; German Study Group on First-Episode Schizophrenia. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia. J Clin Psychiatry
2007; 68: 1763–74.
Lee, SM, Chou, YH, Li, MH, Wan, FJ, Yen, MH. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry
2007; 31: 1101–7.
Saddichha, S, Manjunatha, N, Ameen, S, Akhtar, S. Diabetes and schizophrenia – effect of disease or drug? Results from a randomized, double-blind, controlled prospective study in first-episode schizophrenia. Acta Psychiatr Scand
2008; 117: 342–7.
de Haan, L, van Bruggen, M, Lavalaye, J, Booij, J, Dingemans, PM, Linszen, D. Subjective experience and D2 receptor occupancy in patients with recent-onset schizophrenia treated with low-dose olanzapine or haloperidol: a randomized, double-blind study. Am J Psychiatry
2003; 160: 303–9.
Lieberman, JA, Tollefson, G, Tohen, M, Green, AI, Gur, RE, Kahn, R, et al; HGDH Study Group. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. Am J Psychiatry
2003; 160: 1396–404.
Bustillo, JR, Rowland, LM, Jung, R, Brooks, WM, Qualls, C, Hammond, R, et al. Proton Magnetic Resonance Spectroscopy During Initial Treatment With Antipsychotic Medication in Schizophrenia. Neuropsychopharmacology
2008; 33: 2456–66.
Lieberman, JA, Phillips, M, Gu, H, Stroup, S, Zhang, P, Kong, L, et al. Atypical and conventional antipsychotic drugs in treatment-naive first-episode schizophrenia: a 52-week randomized trial of clozapine vs chlorpromazine. Neuropsychopharmacology
2003; 28: 995–1003.
Wu, RR, Zhao, JP, Zhai, JG, Guo, XF, Guo, WB. Sex difference in effects of typical and atypical antipsychotics on glucose-insulin homeostasis and lipid metabolism in first-episode schizophrenia. J Clin Psychopharmacol
2007; 27: 374–9.
Green, AI, Lieberman, JA, Hamer, RM, Glick, ID, Gur, RE, Kahn, RS, et al; HGDH Study Group. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophr Res
2006; 86: 234–43.
Glenthøj, A, Glenthøj, BY, Mackeprang, T, Pagsberg, AK, Hemmingsen, RP, Jernigan, TL, et al. Basal ganglia volumes in drug-naive first-episode schizophrenia patients before and after short-term treatment with either a typical or an atypical antipsychotic drug. Psychiatry Res
2007; 154: 199–208.
Leucht, S, Kane, JM, Etschel, E, Kissling, W, Hamann, J, Engel, RR. Linking the PANSS, BPRS, and CGI: clinical implications. Neuropsychopharmacology
2006; 31: 2318–25.
Alvarez-Jiménez, M, González-Blanch, C, Crespo-Facorro, B, Hetrick, S, Rodríguez-Sánchez, JM, Pérez-Iglesias, R, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs
2008; 22: 547–62.
Park, S, Ross-Degnan, D, Adams, AS, Sabin, J, Kanavos, P, Soumerai, SB. Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study. Br J Psychiatry
2005; 187: 137–42.
Tyrer, P, Kendall, T. The spurious advance of antipsychotic drug therapy. Lancet
2009; 373: 4–5.
Margolis, RL. Neuropsychiatric disorders: the choice of antipsychotics in schizophrenia. Nat Rev Neurol
2009; 5: 308–310.
Leucht, S, Komossa, K, Rummel-Kluge, C, Corves, C, Hunger, H, Schmid, F, et al. A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry
2009; 166: 152–63.
Perez-Iglesias, R, Crespo-Facorro, B, Martinez-Garcia, O, Ramirez-Bonilla, ML, Alvarez-Jimenez, M, Pelayo-Teran, JM, et al. Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. Schizophr Res
2008; 99: 13–22.
Fagerlund, B, Mackeprang, T, Gade, A, Glenthøj, BY. Effects of low-dose risperidone and low-dose zuclopenthixol on cognitive functions in first-episode drug-naive schizophrenic patients. CNS Spectr
2004; 9: 364–74.
Möller, HJ, Riedel, M, Jäger, M, Wickelmaier, F, Maier, W, Kühn, KU, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol
2008; 11: 985–7.